← FDA DRUG APPROVALS

FDA ANDA · ANDA084869

IMIPRAMINE HYDROCHLORIDE

Sponsor: SANDOZ

APPLICATION
ANDA084869
TYPE
ANDA
ORIGINAL APPROVAL
1994-09-16
LATEST ACTION
1995-04-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

IMIPRAMINE HYDROCHLORIDEDiscontinued
IMIPRAMINE HYDROCHLORIDE 25MG · TABLET · ORAL

Approval history

1995-04-20Labeling · Supplement 34AP
1994-09-16OriginalAP
1993-06-25Labeling · Supplement 33AP
1993-03-12Labeling · Supplement 32AP
1992-07-31Labeling · Supplement 31AP
1989-04-26Labeling · Supplement 23AP
1986-09-09Manufacturing (CMC) · Supplement 21AP
1986-09-09Manufacturing (CMC) · Supplement 18AP
1986-09-09Manufacturing (CMC) · Supplement 20AP
1986-09-09Manufacturing (CMC) · Supplement 19AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →